The global gene therapy for rare pediatric immune deficiencies (Leukocyte Adhesion Deficiency Type I) market was valued at approximately $0.6 billion in 2025 and is projected to grow to $3.8 billion by 2034, expanding at a robust compound annual growth rate (CAGR) of 22.8% over the forecast period 2026-2034. This ultra-orphan segment represents one of the most concentrated and scientifically advanced niches within the broader gene therapy landscape, anchored by the landmark regulatory https://researchintelo.com/rep....ort/gene-therapy-for
লাইক
মন্তব্য করুন
শেয়ার করুন
